#None #Class Action #Securities Fraud #uniQure

uniQure N.V. Class Action Lawsuit Overview

uniQure N.V. (NASDAQ: QURE) is under scrutiny as a securities fraud class action lawsuit has been filed against the company by the law firm Kessler Topaz Meltzer & Check, LLP. This lawsuit specifically addresses the claims made by the firm on behalf of investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025. The class action was officially registered in the United States District Court for the Southern District of New York under the case name Scocco v. uniQure N.V., et al., Case No. 126-cv-01124.

The complaints allege that the biotech company engaged in misleading practices regarding its much-awaited gene therapy treatment for Huntington's disease, called AMT-130. Concerns were raised over material misstatements and omissions concerning the clinical trials for this drug, which aimed to address a significant health issue. Investors have until April 13, 2026, to move the Court for the position of lead plaintiff, and they are encouraged to reach out to the firm for recovery options.

Allegations Against uniQure N.V.

The central allegation in the lawsuit suggests that uniQure failed to disclose crucial information related to its Phase I/II clinical trials, which are essential for the Biologics License Application (BLA) submission to the FDA. Among the key claims, investors were reportedly misled about:
1. The approval status of the pivotal trial design by the FDA.
2. The company's timeline for filing the BLA following the trials, which was supposedly delayed due to the need for additional studies.
3. The overall financial health and prospects of uniQure, which investors were misinformed about, potentially leading to significant financial losses.

The lawsuit alleges that such misrepresentations and failures ultimately resulted in a drastic drop of more than 49% in the share price. Following a revelation on November 3, 2025, that the FDA did not agree with the data implications from the trials, uniQure's stock plummeted from $67.69 per share to just $34.29, causing substantial financial damage to investors.

What Should Affected Investors Do?

With the deadline rapidly approaching, current shareholders of uniQure who acquired shares during the specified period are faced with critical decisions. They can opt to:

• - File to be a Lead Plaintiff: Investors can submit a motion to be the lead plaintiff by the April deadline, thereby taking an active role in directing the course of the litigation.
• - Contact Kessler Topaz Meltzer & Check, LLP: The firm has indicated that there are no costs involved for investors seeking to understand their rights or potential recovery options linked to their investments in uniQure.
• - Remain Inactive: Investors may also choose to stay passive and remain absent from the proceedings as class members. However, this inaction could limit their influence on the case.

The Importance of the Lead Plaintiff Role

Being a lead plaintiff comes with various responsibilities, including overseeing the litigation and selecting counsel for representation on behalf of the entire class. Therefore, it is important for potential lead plaintiffs to consider their financial stake and how representative they can be of the affected investor pool.

About Kessler Topaz Meltzer & Check, LLP

The plaintiffs’ law firm leading this action, Kessler Topaz Meltzer & Check, has established a reputation for pursuing securities fraud cases with a track record of recovering substantial settlements. The firm emphasizes that potential plaintiffs can seek legal counsel without any upfront costs or obligations.

For further information about the class action and to explore options, investors are encouraged to get in touch with Jonathan Naji, Esq. from KTMC. He can provide guidance through the complex legal landscape surrounding the case against uniQure N.V.

In conclusion, as deadlines loom, affected shareholders must act quickly to determine the best course of action regarding their investment in uniQure. By staying informed and connecting with legal experts, investors can better navigate this challenging situation.